HIV相关卡波西肉瘤的肿瘤治疗:40年回顾
本文综述HIV相关卡波西肉瘤(HIV+KS)的发病机制及当前免疫治疗和靶向KS发病机制的治疗证据。HIV+KS在部分HIV感染人群中持续存在,在撒哈拉以南非洲为最常见肿瘤之一,因复发缓解特性可致显著长期并发症。文章回顾了流行病学早期临床试验探索的化疗药物,强调CD4淋巴细胞减少和免疫失调背景下保留T细胞治疗选择的重要性,并讨论HIV合并肿瘤患者的管理问题。
要点
- HIV+KS在部分HIV感染人群中持续存在,在撒哈拉以南非洲为最常见肿瘤之一。
- HIV+KS因复发缓解特性可导致显著长期并发症,部分患者合并淋巴增殖综合征、恶性肿瘤和/或感染。
- CD4淋巴细胞减少和免疫失调背景下,保留T细胞的治疗选择很重要。
核心结论
- 本文综述HIV+KS的发病机制及当前免疫治疗和靶向KS发病机制的治疗证据,强调CD4淋巴细胞减少和免疫失调背景下保留T细胞治疗选择的重要性。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- HIV+KS在部分HIV感染人群中持续存在,在撒哈拉以南非洲为最常见肿瘤之一。
- HIV+KS因复发缓解特性可导致显著长期并发症,部分患者合并淋巴增殖综合征、恶性肿瘤和/或感染,可导致死亡。
- 流行病学早期临床试验探索了多种化疗药物治疗HIV+KS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The observation in 1981 of the emergence of Kaposi sarcoma (KS) among young men who had sex with men was one of the first harbingers of the HIV epidemic. With advances in HIV care, the incidence of HIV-associated KS (HIV+KS) has decreased over time in the United States. However, it remains a persistent malignancy among some HIV-infected populations and is one of the most common tumors in sub-Saharan Africa. Because of the relapsing and remitting nature of this cancer, patients with HIV+KS can experience significant, long-term, morbidity. Patients with severe HIV+KS may also have concurrent lymphoproliferative syndromes, malignancies, and/or infections that can contribute to mortality. Several chemotherapy agents were explored in clinical trials for HIV+KS during the early stage of the epidemic. As HIV+KS emerges with CD4 lymphopenia and immunodysregulation, T-cell-sparing options are important to consider. Here, we explore the pathogenesis of HIV+KS and the current evidence for immunotherapy and therapies that potentially target KS pathogenesis. This review provides the current landscape of therapies for HIV+KS and highlights management issues for patients with HIV and cancer.
引用
- Ramaswami R, Lurain K, Yarchoan R, et al. Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. J Clin Oncol. 2021. PMID: 34890242. doi:10.1200/JCO.21.02040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。